William Blair & Company
VRTX icon

William Blair & Company’s Vertex Pharmaceuticals VRTX Stock Holding History

William Blair & Company’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.39M Buy
16,541
+451
+3% +$210K 0.02% 416
2025
Q4 		$7.29M Sell
16,090
-1,900
-11% -$819K 0.02% 428
2025
Q3 		$7.05M Sell
17,990
-8,087
-31% -$3.38M 0.02% 441
2025
Q2 		$11.6M Sell
26,077
-768
-3% -$354K 0.03% 324
2025
Q1 		$13M Buy
26,845
+201
+0.8% +$93.7K 0.04% 285
2024
Q4 		$10.7M Sell
26,644
-64,672
-71% -$30M 0.03% 328
2024
Q3 		$42.5M Buy
91,316
+2,208
+2% +$1.06M 0.12% 138
2024
Q2 		$41.8M Buy
89,108
+18,197
+26% +$7.9M 0.13% 135
2024
Q1 		$29.6M Buy
70,911
+6,937
+11% +$2.93M 0.09% 169
2023
Q4 		$26M Buy
63,974
+45,128
+239% +$16.7M 0.09% 176
2023
Q3 		$6.55M Buy
18,846
+581
+3% +$203K 0.03% 382
2023
Q2 		$6.43M Buy
18,265
+73
+0.4% +$24.6K 0.02% 396
2023
Q1 		$5.73M Buy
18,192
+548
+3% +$164K 0.02% 411
2022
Q4 		$5.1M Sell
17,644
-169
-0.9% -$51.5K 0.02% 425
2022
Q3 		$5.16M Sell
17,813
-142
-0.8% -$40.9K 0.02% 400
2022
Q2 		$5.06M Sell
17,955
-578
-3% -$155K 0.02% 416
2022
Q1 		$4.84M Sell
18,533
-4,956
-21% -$1.18M 0.02% 473
2021
Q4 		$5.16M Buy
23,489
+7,239
+45% +$1.41M 0.02% 470
2021
Q3 		$2.95M Sell
16,250
-6,500
-29% -$1.27M 0.01% 595
2021
Q2 		$4.59M Sell
22,750
-3,289
-13% -$688K 0.02% 471
2021
Q1 		$5.6M Sell
26,039
-2,370
-8% -$521K 0.02% 432
2020
Q4 		$6.71M Sell
28,409
-4,316
-13% -$990K 0.02% 381
2020
Q3 		$8.9M Sell
32,725
-17
-0.1% -$4.69K 0.04% 292
2020
Q2 		$9.51M Buy
32,742
+5,319
+19% +$1.44M 0.05% 271
2020
Q1 		$6.53M Buy
27,423
+135
+0.5% +$31K 0.04% 286
2019
Q4 		$5.97M Buy
27,288
+4,945
+22% +$1M 0.03% 361
2019
Q3 		$3.79M Sell
22,343
-1,383
-6% -$245K 0.02% 431
2019
Q2 		$4.35M Buy
23,726
+5,467
+30% +$956K 0.02% 406
2019
Q1 		$3.36M Buy
18,259
+10,327
+130% +$1.91M 0.02% 438
2018
Q4 		$1.31M Buy
7,932
+1,669
+27% +$289K 0.01% 622
2018
Q3 		$1.21M Buy
6,263
+47
+0.8% +$8.37K 0.01% 686
2018
Q2 		$1.06M Buy
6,216
+157
+3% +$24.3K 0.01% 707
2018
Q1 		$987K Buy
6,059
+42
+0.7% +$6.86K 0.01% 717
2017
Q4 		$902K Buy
6,017
+14
+0.2% +$2.07K 0.01% 772
2017
Q3 		$913K Sell
6,003
-8
-0.1% -$1.2K 0.01% 755
2017
Q2 		$775K Hold
6,011
– – 0.01% 832
2017
Q1 		$645K Sell
6,011
-110
-2% -$9.68K 0.01% 828
2016
Q4 		$451K Sell
6,121
-1,149
-16% -$93.5K ﹤0.01% 871
2016
Q3 		$634K Sell
7,270
-3
-0% -$284 0.01% 762
2016
Q2 		$626K Buy
7,273
+309
+4% +$26.7K 0.01% 736
2016
Q1 		$553K Buy
6,964
+565
+9% +$51.1K 0.01% 765
2015
Q4 		$805K Sell
6,399
-7,896
-55% -$953K 0.01% 677
2015
Q3 		$1.49M Buy
14,295
+7,826
+121% +$1.01M 0.01% 622
2015
Q2 		$798K Hold
6,469
– – ﹤0.01% 1632
2015
Q1 		$762K Sell
6,469
-425
-6% -$50.9K ﹤0.01% 1624
2014
Q4 		$818K Buy
6,894
+624
+10% +$70.3K ﹤0.01% 1551
2014
Q3 		$704K Buy
6,270
+34
+0.5% +$3.24K ﹤0.01% 1584
2014
Q2 		$590K Sell
6,236
-698
-10% -$48.9K ﹤0.01% 1616
2014
Q1 		$490K Buy
6,934
+344
+5% +$27.2K ﹤0.01% 1624
2013
Q4 		$490K Sell
6,590
-1,065
-14% -$74.2K ﹤0.01% 1598
2013
Q3 		$580K Sell
7,655
-1,915
-20% -$152K ﹤0.01% 1510
2013
Q2 		$764K Buy
+9,570
New +$705K ﹤0.01% 1368

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

William Blair & Company's VRTX Position: Q1 2026 in Review

William Blair & Company increased its Vertex Pharmaceuticals (VRTX) stake by 2.8% in Q1 2026, buying an estimated $210K and bringing the position to 16,541 shares worth $7.39M. The position accounts for 0.02% of the portfolio, ranked #416.

William Blair & Company first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $42.5M in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • William Blair & Company held 16,541 shares of Vertex Pharmaceuticals worth $7.39M as of Q1 2026.
  • William Blair & Company bought 451 Vertex Pharmaceuticals shares in Q1 2026, an estimated $210K.
  • Vertex Pharmaceuticals made up 0.02% of William Blair & Company's portfolio in Q1 2026, its #416 holding.
  • William Blair & Company first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • William Blair & Company's Vertex Pharmaceuticals position peaked at $42.5M in Q3 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.